- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
People
Gary Messplay specializes in advising life science companies on regulatory and compliance matters. A partner in our FDA and Life Sciences practice, Gary represents leading pharmaceutical and medical device companies in a broad range of regulatory and compliance matters. Gary's clients include large multinational drug and device companies, as well as emerging companies.
Gary represents clients in matters relating to the regulation and commercialization of drugs, biologics, medical devices, food, cosmetics and tobacco by the Food and Drug Administration, the Department of Health and Human Services, the Department of Agriculture, the Drug Enforcement Administration, and other federal and state agencies. He counsels large multinational product manufacturers, as well as mid-size and emerging companies, on regulatory and compliance matters that involve the FDA, the HHS Office of Inspector General and other government agencies.
Gary has substantial experience in advising clients on all aspects of product launches and commercialization; leading product and compliance-related investigations; developing and implementing regulatory and healthcare compliance programs; and managing competitor disputes.
In addition, Gary regularly advises clients on complex regulatory and administrative law matters; compliance; advertising and promotion; specialty pharmacy programs; litigation; legislative initiatives; and due diligence in financings, mergers and acquisitions. He also advises clients on matters relating to healthcare fraud and abuse, clinical trials, drug safety issues, recalls, product approval issues, drug and device quality and manufacturing issues, and life cycle management. Counseling clients in responding to government and congressional investigations, as well as in transactional work related to FDA- and USDA-regulated products, is also a part of Gary's practice.
Previously, Gary was in-house counsel at Eli Lilly and Company, where he had global legal, regulatory and compliance responsibility for the company's top-selling pharmaceutical product at the time.
A frequent author and speaker on regulatory and compliance matters, Gary has been recognized for multiple years by Super Lawyers.
Credentials
District of Columbia
Indiana
Close
Recognition
Super Lawyers, 2014, 2015 & 2016
News
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Matters
Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies.
Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies.
Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory.
See more
Close
Matters
Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies.
Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies.
Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory.
Advised numerous drug and device companies related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement.
Conducted a significant number of compliance investigations on behalf of drug and device companies, including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling.
Represented Board of Directors of publicly traded pharmaceutical company in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute.
Advised drug and device companies on all aspects of compliance with their corporate integrity agreements.
Advised numerous pharmaceutical companies on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues.
Successfully represented a specialty pharmaceutical company in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication.
Represented drug and device companies in connection with FDA, OCI, Department of Justice, SEC and congressional investigations.
Advised drug and device companies related to clinical trial regulatory and compliance issues.
Assisted pharmaceutical companies in developing and implementing specialty pharmacy programs.
Represented drug and device companies in connection with adverse FDA inspections, including responding to 483s and warning letters.
Represented drug and device companies in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements.
Led numerous regulatory and compliance due diligence teams in drug, device, tobacco and food transactions.
Represented drug and device companies in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation.
Advised drug, biotechnology, device, food and tobacco companies on legislative matters including drafting and commenting on legislation.
Insights
Client Alert
April 22, 2021
Development of Biosimilar and Interchangeable Biological Products During the COVID-19 Pandemic: What the ANDA Guidance Left Unsaid
Client Alert
February 28, 2020
2019 Year in Review: FDA Office of Prescription Drug Promotion
Client Alert
February 7, 2020
FDA Releases Draft Guidance on Promotion of Biological Reference and Biosimilar Products
News
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Matters
Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies.
Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies.
Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory.
See more
Close
Matters
Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies.
Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies.
Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory.
Advised numerous drug and device companies related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement.
Conducted a significant number of compliance investigations on behalf of drug and device companies, including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling.
Represented Board of Directors of publicly traded pharmaceutical company in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute.
Advised drug and device companies on all aspects of compliance with their corporate integrity agreements.
Advised numerous pharmaceutical companies on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues.
Successfully represented a specialty pharmaceutical company in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication.
Represented drug and device companies in connection with FDA, OCI, Department of Justice, SEC and congressional investigations.
Advised drug and device companies related to clinical trial regulatory and compliance issues.
Assisted pharmaceutical companies in developing and implementing specialty pharmacy programs.
Represented drug and device companies in connection with adverse FDA inspections, including responding to 483s and warning letters.
Represented drug and device companies in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements.
Led numerous regulatory and compliance due diligence teams in drug, device, tobacco and food transactions.
Represented drug and device companies in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation.
Advised drug, biotechnology, device, food and tobacco companies on legislative matters including drafting and commenting on legislation.
Insights
Client Alert
April 22, 2021
Development of Biosimilar and Interchangeable Biological Products During the COVID-19 Pandemic: What the ANDA Guidance Left Unsaid
Client Alert
February 28, 2020
2019 Year in Review: FDA Office of Prescription Drug Promotion
Client Alert
February 7, 2020
FDA Releases Draft Guidance on Promotion of Biological Reference and Biosimilar Products
News
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Credentials
District of Columbia
Indiana
Close
Recognition
Super Lawyers, 2014, 2015 & 2016